Dec 8 (Reuters) – BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was shown to generate a neutralising effect against the new Omicron variant in a laboratory test.
In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said in a joint statement that two vaccine doses resulted in significantly lower neutralising antibodies but that a third dose of their vaccine increased the neutralising antibodies by a factor of 25.
They added that, if needed, they can deliver an Omicron-based vaccine in March 2022.
(Reporting by Ludwig Burger; editing by Jason Neely)
Source: Read Full Article